Zhou et al. developed exosomes modified with oxaliplatin prodrug to deliver galectin-9 siRNA to PDAC tissues, which induced immunogenic cell death (ICD) of tumor cells and showed significant therapeutic effects on PDAC (Zhou et al., 2021). Here, LGALS9 is linked to neoplasm.